Hansoh’s Fulaidi (Repaglinide Tablets)  (1.0mg) was approved by National Medical Products Administration and passed the quality and efficacy consistency evaluation of generic drugs on Dec 13, 2018. We are the first in China to pass the consistency evaluation of Repaglinide Tablets.

Repaglinide is a non-sulfonylurea insulin-producing hypoglycemic agent mainly indicated for the treatment of type 2 diabetes.